Actelion Share Price

Stocks

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
22/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
15/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	+0.99%	-	-	0
WUXI APPTEC CO., LTD.	+2.02%	+1.26%	+41.37%	+105.18%	69.19B
ARGENX SE	-0.97%	-4.80%	+31.34%	+74.37%	62.97B
INSMED INCORPORATED	-1.11%	+2.78%	-14.86%	+375.59%	27.27B
BIONTECH SE	-4.92%	-3.22%	-3.90%	-17.87%	24.78B
WUXI BIOLOGICS (CAYMAN) INC.	-1.18%	-0.97%	+29.47%	+14.19%	25.8B
GENMAB A/S	+0.23%	-0.23%	+23.37%	-16.28%	20.11B
PHARMAESSENTIA CORPORATION	+6.04%	+7.25%	+233.25%	+383.12%	18.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.52%	-2.52%	-8.19%	+515.36%	14.88B
EXELIXIS, INC.	-2.27%	+1.37%	+53.01%	+160.83%	14.29B
Average	-0.36%	+0.74%	+42.76%	+177.17%	30.86B
Weighted average by Cap.	-0.15%	+0.11%	+37.83%	+139.84%